Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome

References

• Bernadich C, Bandi JC, Melin P, Bosch J. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology27(2), 351–356 (1998).
   PubMed Web of Science ®Google Scholar
• Saner F, Kavuk I, Lang H et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur. J. Med. Res.9(2), 78–82 (2004).
   PubMedGoogle Scholar
• Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology36(4 Pt 1), 941–948 (2002).
   PubMed Web of Science ®Google Scholar
• Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J. Hepatol.33(1), 43–48 (2000).
   PubMed Web of Science ®Google Scholar
• Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation95(5), 1122–1125 (1997).
   PubMed Web of Science ®Google Scholar
• Salluh JI, Martins GA, Santino MS, Araujo LV, Freitas GG, Verdeal JC. Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury. Acta Anaesthesiol. Scand.51(4), 505–508 (2007).
   PubMedGoogle Scholar
• Henriksen JH, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J. Hepatol.31(4), 712–718 (1999).
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Bendtsen F, Sorensen TI, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology97(6), 1506–1513 (1989).
   PubMed Web of Science ®Google Scholar
• Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet362(9398), 1819–1827 (2003).
   PubMed Web of Science ®Google Scholar
• Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J. Hepatol.32(1 Suppl.), 157–170 (2000).
   PubMed Web of Science ®Google Scholar
• Moerer O, Schmid A, Hofmann M et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med.28(10), 1440–1446 (2002).
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am. J. Respir. Crit. Care Med.154(3 Pt 1), 617–624 (1996).
   PubMed Web of Science ®Google Scholar
• Chernow B, Roth BL. Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ. Shock18(2), 141–155 (1986).
   PubMedGoogle Scholar
• Morelli A, Rocco M, Conti G et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med.30(4), 597–604 (2004).
   PubMed Web of Science ®Google Scholar
• Boccara G, Ouattara A, Godet G et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin–angiotensin system inhibitors. Anesthesiology98(6), 1338–1344 (2003).
   PubMed Web of Science ®Google Scholar
• Chiu KW, Sheen IS, Liaw YF. A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices. J. Gastroenterol. Hepatol.5(5), 549–553 (1990).
   PubMedGoogle Scholar
• Moreau R, Soubrane O, Hadengue A et al. Hemodynamic effects of the administration of terlipressin alone or combined with nitroglycerin in patients with cirrhosis. Gastroenterol. Clin. Biol.16(8–9), 680–686 (1992).
   PubMedGoogle Scholar
• Nevens F, Van Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut38(1), 129–134 (1996).
   PubMedGoogle Scholar
• Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment. Pharmacol. Ther.17(1), 53–64 (2003).
   PubMed Web of Science ®Google Scholar
• Feu F, Ruiz del Arbol L, Banares R, Planas R, Bosch J. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology111(5), 1291–1299 (1996).
   PubMed Web of Science ®Google Scholar
• Guevara M, Gines P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology27(1), 35–41. (1998).
   PubMed Web of Science ®Google Scholar
• Villanueva C, Ortiz J, Minana J et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology121(1), 110–117 (2001).
   PubMedGoogle Scholar
• Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology80(3), 518–525 (1981).
   PubMed Web of Science ®Google Scholar
• Cirera I, Feu F, Luca A et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology22(1), 106–111 (1995).
   PubMed Web of Science ®Google Scholar
• Burroughs AK, McCormick PA, Hughes MD, Sprengers D, D’Heygere F, McIntyre N. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology99(5), 1388–1395 (1990).
   PubMed Web of Science ®Google Scholar
• Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet350(9090), 1495–1499 (1997).
   PubMed Web of Science ®Google Scholar
• Valenzuela JE, Schubert T, Fogel MR et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology10(6), 958–961 (1989).
   PubMed Web of Science ®Google Scholar
• Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ310(6993), 1495–1498 (1995).
   PubMedGoogle Scholar
• Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J. Hepatol.26(5), 1018–1025 (1997).
   PubMedGoogle Scholar
• Zironi G, Rossi C, Siringo S et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study. Liver16(4), 225–234 (1996).
   PubMedGoogle Scholar
• Escorsell A, Bandi JC, Andreu V et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology120(1), 161–169 (2001).
   PubMed Web of Science ®Google Scholar
• Avgerinos A, Armonis A, Rekoumis G, Manolakopoulos S, Argirakis G, Raptis S. The effect of somatostatin and octreotide on intravascular oesophageal variceal pressure in patients with cirrhosis. J. Hepatol.22(3), 379–380 (1995).
   PubMedGoogle Scholar
• Moller S, Christensen E, Henriksen JH. Continuous blood pressure monitoring in cirrhosis. Relations to splanchnic and systemic haemodynamics. J. Hepatol.27(2), 284–294 (1997).
   PubMedGoogle Scholar
• Albillos A, Rossi I, Iborra J et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J. Hepatol.21(1), 88–94 (1994).
   PubMedGoogle Scholar
• Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am. J. Gastroenterol.95(3), 768–771 (2000).
   PubMedGoogle Scholar
• Sung JJ, Chung SC, Yung MY et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet346(8991–8992), 1666–1669 (1995).
   PubMed Web of Science ®Google Scholar
• Besson I, Ingrand P, Person B et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N. Engl. J. Med.333(9), 555–560 (1995).
   PubMedGoogle Scholar
• Group IVOS BA. Double blind RCT of 5 days octreotide versus placebo, associated with sclerotherapy for trial/failures. Hepatology24, 352A (1996) (Abstract).
   PubMedGoogle Scholar
• Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices. Cochrane Database Syst. Rev.2, CD000193 (2000).
   Google Scholar
• Cales P, Masliah C, Bernard B et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N. Engl. J. Med.344(1), 23–28 (2001).
   PubMed Web of Science ®Google Scholar
• Part 6: advanced cardiovascular life support. Section 6: pharmacology II: agents to optimize cardiac output and blood pressure. European Resuscitation Council. Resuscitation46(1–3), 155–162 (2000).
   PubMedGoogle Scholar
• Landry DW, Levin HR, Gallant EM et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit. Care Med.25(8), 1279–1282 (1997).
   PubMed Web of Science ®Google Scholar
• Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology96(3), 576–582 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet359(9313), 1209–1210 (2002).
   PubMed Web of Science ®Google Scholar
• Oliver H, Shafer E. On the physiologic action of extracts of the pituitary body and certain other glandular organs. J. Physiol. (Lond.)18, 277–279 (1895).
   Google Scholar
• Von den Velden R. Die nierenwirkung von hypophysenextrakten beim menschen. Berl. Klin. Wochenschr.50, 2083–2086 (1913).
   Google Scholar
• Aronsen KF, Bjorkman I, Lindstrom K, Nylander G, Mulder J. The mechanism of lysine-vasopressin hemostasis in bleeding esophageal varices. Acta Chir. Scand.145(4), 231–234 (1979).
   PubMedGoogle Scholar
• Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver20(1), 51–59 (2000).
   PubMedGoogle Scholar
• Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J. Clin. Gastroenterol.11(1), 58–60 (1989).
   PubMed Web of Science ®Google Scholar
• Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest120(3), 989–1002 (2001).
   PubMed Web of Science ®Google Scholar
• Kusano E, Tian S, Umino T, Tetsuka T, Ando Y, Asano Y. Arginine vasopressin inhibits interleukin-1 β-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J. Hypertens.15(6), 627–632 (1997).
   PubMed Web of Science ®Google Scholar
• Wakatsuki T, Nakaya Y, Inoue I. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am. J. Physiol.263(2 Pt 2), H491–H496 (1992).
   PubMed Web of Science ®Google Scholar
• Lee WC, Lin HC, Yang YY et al. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis. Am. J. Gastroenterol.96(4), 1210–1216 (2001).
   PubMedGoogle Scholar
• Moller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can. J. Gastroenterol.15(2), 94–106 (2001).
   PubMed Web of Science ®Google Scholar
• Saner F, Kavuk I, Lang H et al. Postoperative ICU management in liver transplant patients. Eur. J. Med. Res.8(11), 511–516 (2003).
   PubMedGoogle Scholar
• Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp. Clin. Res.16(6), 307–314 (1990).
   PubMedGoogle Scholar
• Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology6(1), 112–115 (1986).
   PubMed Web of Science ®Google Scholar
• Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand. J. Gastroenterol.25(6), 622–630 (1990).
   PubMed Web of Science ®Google Scholar
• Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet346(8979), 865–868 (1995).
   PubMed Web of Science ®Google Scholar
• Pauwels A, Florent C, Desaint B, Guivarch P, Van H, Levy VG. Terlipressin and somatostatin in the treatment of hemorrhages from rupture of esophageal varices. Gastroenterol. Clin. Biol.18(4), 388–389 (1994).
   PubMedGoogle Scholar
• Garcia-Compean D, Blanc P, Bories JM et al. Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic balloon in patients with cirrhosis. A randomized controlled trial. Arch. Med. Res.28(2), 241–245 (1997).
   PubMedGoogle Scholar
• Fort E, Sautereau D, Silvain C, Ingrand P, Pillegand B, Beauchant M. A randomized trial of terlipressin plus nitroglycerin vs. balloon tamponade in the control of acute variceal hemorrhage. Hepatology11(4), 678–681 (1990).
   PubMed Web of Science ®Google Scholar
• Silvain C, Carpentier S, Sautereau D et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology18(1), 61–65 (1993).
   PubMedGoogle Scholar
• Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin. Investig.72(9), 653–659 (1994).
   PubMedGoogle Scholar
• Walker S, Kreichgauer HP, Bode JC. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices – final report of a placebo-controlled, double-blind study. Z. Gastroenterol.34(10), 692–698 (1996).
   PubMedGoogle Scholar
• Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig. Dis. Sci.41(6), 1054–1056 (1996).
   PubMedGoogle Scholar
• Cervoni JP, Lecomte T, Cellier C et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am. J. Gastroenterol.92(11), 2113–2114. (1997).
   PubMedGoogle Scholar
• Le Moine O, el Nawar A, Jagodzinski R et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol. Belg.61(2), 268–270. (1998).
   PubMed Web of Science ®Google Scholar
• Hadengue A, Gadano A, Moreau R et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol.29(4), 565–570 (1998).
   PubMed Web of Science ®Google Scholar
• Mulkay JP, Louis H, Donckier V et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol. Belg.64(1), 15–19 (2001).
   PubMed Web of Science ®Google Scholar
• Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur. J. Gastroenterol. Hepatol.14(12), 1363–1368 (2002).
   PubMed Web of Science ®Google Scholar
• Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology122(4), 923–930 (2002).
   PubMed Web of Science ®Google Scholar
• Saner FH, Fruhauf NR, Schafers RF, Lang H, Malago M, Broelsch CE. Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur. J. Gastroenterol. Hepatol.15(8), 925–927 (2003).
   PubMedGoogle Scholar
• Sanyal A, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Teuber P. A prospective, randomized, double blind, placebo-controlled trial of telipressin for type 1 hepatorenal syndrome (HRS). Hepatology44(4, Suppl 1), 694A (2006).
   PubMed Web of Science ®Google Scholar
• Rittig S, Arentsen J, Sorensen K, Matthiesen T, Dupont E. The hemodynamic effects of triglycyl-lysine-vasopressin (Glypressin) in patients with parkinsonism and orthostatic hypotension. Mov. Disord.6(1), 21–28 (1991).
   PubMedGoogle Scholar
• Eyraud D, Brabant S, Nathalie D et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth. Analg.88(5), 980–984 (1999).
   PubMed Web of Science ®Google Scholar
• Scharte M, Meyer J, Van Aken H, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit. Care Med.29(9), 1756–1760 (2001).
   PubMed Web of Science ®Google Scholar
• Medel J, Boccara G, Van de Steen E, Bertrand M, Godet G, Coriat P. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth. Analg.93(1), 53–55 (2001).
   PubMed Web of Science ®Google Scholar
• Asfar P, Pierrot M, Veal N et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit. Care Med.31(1), 215–220 (2003).
   PubMed Web of Science ®Google Scholar
• Asfar P, Hauser B, Ivanyi Z et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit. Care Med.33(2), 373–380 (2005).
   PubMed Web of Science ®Google Scholar
• Lange M, Morelli A, Ertmer C et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock (2007) (Epub ahead of print).
   Google Scholar
• Jolley DH, De Keulenaer BL, Potter A, Stephens DP. Terlipressin infusion in catecholamine-resistant shock. Anaesth. Intensive Care31(5), 560–564 (2003).
   PubMed Web of Science ®Google Scholar
• Albanese J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit. Care Med.33(9), 1897–1902 (2005).
   PubMed Web of Science ®Google Scholar
• Peters MJ, Booth RA, Petros AJ. Terlipressin bolus induces systemic vasoconstriction in septic shock. Pediatr. Crit. Care Med.5(2), 112–115 (2004).
   PubMedGoogle Scholar
• Zeballos G, Lopez-Herce J, Fernandez C, Brandstrup KB, Rodriguez-Nunez A. Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation68(1), 151–153 (2006).
   PubMed Web of Science ®Google Scholar
• Matok I, Leibovitch L, Vardi A et al. Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatr. Crit. Care Med.5(2), 116–118 (2004).
   PubMedGoogle Scholar
• Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, Gonzalez-Alonso N, Martinon-Sanchez JM. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med.30(3), 477–480 (2004).
   PubMed Web of Science ®Google Scholar
• Matok I, Vard A, Efrati O et al. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock23(4), 305–310 (2005).
   PubMedGoogle Scholar
• Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, Hernandez A, Rey C. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit. Care10(1), R20 (2006).
   PubMedGoogle Scholar
• Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit. Care Med.30(8), 1899–1901 (2002).
   PubMedGoogle Scholar
• Grant PJ, Tate GM, Davies JA, Williams NS, Prentice CR. Intra-operative activation of coagulation – a stimulus to thrombosis mediated by vasopressin? Thromb. Haemost.55(1), 104–107 (1986).
   PubMedGoogle Scholar
• Gazmuri RJ, Ayoub IM. Pressors for cardiopulmonary resuscitation: is there a new kid on the block? Crit. Care Med.28(4), 1236–1238 (2000).
   PubMedGoogle Scholar
• Dunser MW, Fries DR, Schobersberger W et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth. Analg.99(1), 201–206 (2004).
   PubMed Web of Science ®Google Scholar
• Dunser MW, Mayr AJ, Ulmer H et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation107(18), 2313–2319 (2003).
   PubMed Web of Science ®Google Scholar
• Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology23(1), 164–176. (1996).
   PubMed Web of Science ®Google Scholar
• Dohler KD, Walker S, Mentz P, Forssmann K, Staritz M. Vasoconstrictive therapies for bleeding esophageal varices and their mechanisms of action. Z. Gastroenterol.41(10), 1001–1016 (2003).
   PubMedGoogle Scholar
• Holmes CL, Landry DW, Granton JT. Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology. Crit. Care8(1), 15–23 (2004).
   PubMed Web of Science ®Google Scholar
• Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. Shock22(4), 314–319 (2004).
   PubMed Web of Science ®Google Scholar
• Saner FKI, Lang H, Biglarnia, Fruehauf N, Malagò M, Broelsch CE. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur. J. Med. Res.9(2), 78–82 (2004).
   PubMedGoogle Scholar